RESEARCHER PROFILE

Laura J. Esserman

← Back to University of California, San Francisco

L

University of California, San Francisco

Breast Cancer Treatment StudiesBreast Lesions and CarcinomasMRI in cancer diagnosisBRCA gene mutations in cancerDigital Radiography and Breast Imaging

Laura J. Esserman works in Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, MRI in cancer diagnosis, BRCA gene mutations in cancer, Digital Radiography and Breast Imaging. Recorded institutional associations include University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center.

988Publications
36,531Citations
94H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

    2006 · 1,317 citations
  2. Whole-genome analysis informs breast cancer response to aromatase inhibition

    2012 · 1,023 citations
  3. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

    2013 · 831 citations
  4. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

    2010 · 772 citations
  5. I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

    2009 · 766 citations
  6. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

    2020 · 707 citations
  7. Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

    2012 · 625 citations
  8. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

    2020 · 564 citations
  9. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    2016 · 554 citations
  10. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    2011 · 551 citations
  11. Rethinking Screening for Breast Cancer and Prostate Cancer

    2009 · 516 citations
  12. Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

    2012 · 502 citations
  13. Addressing overdiagnosis and overtreatment in cancer: a prescription for change

    2014 · 501 citations
  14. Leukocyte composition of human breast cancer

    2011 · 479 citations
  15. Overdiagnosis and Overtreatment in Cancer

    2013 · 467 citations
  16. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

    2020 · 462 citations
  17. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    2021 · 456 citations
  18. Adaptive Randomization of Neratinib in Early Breast Cancer

    2016 · 454 citations
  19. Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

    2012 · 438 citations
  20. Personalized early detection and prevention of breast cancer: ENVISION consensus statement

    2020 · 438 citations
  21. Adaptive platform trials: definition, design, conduct and reporting considerations

    2019 · 412 citations
  22. Utility of Magnetic Resonance Imaging in the Management of Breast Cancer: Evidence for Improved Preoperative Staging

    1999 · 379 citations
  23. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

    2012 · 378 citations
  24. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

    2017 · 366 citations
  25. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

    2011 · 362 citations

← Return to the university profile